文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

术后换用替诺福韦对比恩替卡韦维持治疗对肝细胞癌复发的影响(SWITE):随机对照试验研究方案

The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2023-12-02

SWITE是一项前瞻性、随机、开放标签、单中心III期试验,计划纳入238例术后HBV相关肝细胞癌患者,按1:1随机分为换用替诺福韦二吡呋酯(TDF)组或继续恩替卡韦(ETV)维持组,主要终点为3年无复发生存期,次要终点为3年总生存期。

要点

  • 术后换用TDF对比继续ETV维持,主要终点为3年无复发生存期。
  • 计划入组238例术前长期接受ETV治疗的HBV相关肝细胞癌术后患者。
  • 次要终点为3年总生存期,安全性事件将严格记录。

核心结论

  • 手术前长期ETV治疗后换用TDF治疗的生存获益仍不确定,SWITE试验旨在对比TDF换药与ETV维持在HBV相关肝细胞癌术后的效果。

研究设计与样本

  • 前瞻性、随机、开放标签、单中心、III期试验,两组平行对照,计划入组238例术前长期接受ETV治疗的HBV相关肝细胞癌术后患者,按1:1随机分为TDF换药组或ETV维持组。

主要发现

  • 原文未报告结果数据。

关键数值与推荐

  • 主要终点为3年无复发生存期(RFS),次要终点为肝细胞癌根治性手术后3年总生存期(OS),安全性事件将严格记录。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antiviral therapy has been reported to be associated with lower recurrence rate of hepatocellular carcinoma (HCC) for patients with hepatitis B virus (HBV) infection. While entecavir (ETV) and tenofovir disoproxil fumarate (TDF) were both recommended as first-line therapies for HBV patients, recent retrospective studies proposed a lower incidence rate of HCC occurrence or recurrence in those receiving TDF compared ETV. However, the survival benefits of switching to TDF therapy after prolonged ETV treatment before surgery remain uncertain. We delineate the rationale and design of SWITE, a randomized, open-label, phase III trial contrasting TDF switch therapy versus ETV maintenance in HBV-related HCC patients. METHODS AND ANALYSIS: This is a prospective, randomized, controlled, single-center study with two parallel groups of patients with HBV-related HCC who have received long-term ETV therapy before surgery. West China Hospital will enroll 238 patients, randomized in a 1:1 ratio to TDF switch therapy or ETV maintenance after surgery. The primary endpoint of this study is 3-year recurrence free survival (RFS), with the secondary endpoint being 3-year overall survival (OS) after curative surgery of HCC. Safety events will be diligently recorded. ETHICS AND DISSEMINATION: The study protocol aligns with the ethical guidelines of the 1975 Declaration of Helsinki. It was approved by ethics committee of West China Hospital (approval number: 2022-074) and was registered with chictr.org.cn (chiCTR2200057867). Informed consent will be obtained from all participants. The results of this trial will be published in peer-reviewed journals and presentations at national and international conferences relevant to this topic. TRIAL REGISTRATION: chiCTR2200057867 . Date of registration is March 20 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Peng W, Yi M, Qi X, et al. The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial. Trials. 2023. PMID: 38042834. doi:10.1186/s13063-023-07822-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。